橡楚编辑部 8/12/2026 50 min read
This article provides a detailed interpretation of liquid silicone rubber (LSR) parts for medical devices, sorting out their core properties such as biocompatibility, high and low temperature resistance, and disinfection resistance. It introduces the production control standards and compliance requirements of medical-grade LSR parts, and covers their specific applications in different medical scenarios such as surgical instruments, drug delivery devices, and nursing consumables, providing practical references for parts selection and supply chain management in the medical industry.
Liquid Silicone Rubber (LSR) has emerged as a dominant material for high-precision medical device components over the past two decades, driven by its unique combination of biocompatibility, mechanical stability, and process scalability. Unlike conventional thermoplastics or cured solid silicones, LSR is a two-part, platinum-catalyzed elastomer that undergoes cross-linking at elevated temperatures to form a non-degradable, low-friction polymer matrix. For medical applications, LSR parts are deployed across 60% of Class II and 75% of Class III device categories, per 2024 data from the U.S. Food and Drug Administration (FDA), including implantable components, surgical instrument interfaces, drug delivery system seals, and diagnostic device fluid pathways.
The global market for medical device LSR parts is projected to reach $4.2 billion by 2028, growing at a 7.8% CAGR, as device manufacturers prioritize materials that reduce adverse patient events, simplify sterilization workflows, and support miniaturization of portable and wearable medical technologies. This analysis breaks down the core performance features of medical-grade LSR components, standardized testing and regulatory frameworks governing their deployment, precision manufacturing process controls, and emerging application trends that are reshaping the medical device landscape.
The widespread adoption of LSR in medical components stems from its intrinsic material properties, which can be tuned to meet the unique demands of acute care, long-term implantation, and single-use device applications. Unlike alternative materials such as polyvinyl chloride (PVC), polyethylene (PE), or natural rubber, LSR eliminates common failure points including plasticizer leaching, environmental stress cracking, and protein adhesion, while supporting a wider range of operating conditions.
Biological safety is the non-negotiable baseline for all medical device LSR parts, and LSR outperforms most competing elastomers across all relevant biocompatibility metrics. Medical-grade LSR formulations are free of endocrine-disrupting phthalates, latex allergens, and heavy metal curing agents, making them suitable for contact with sensitive tissue, blood, and pharmaceutical products. Table 1 summarizes the core biocompatibility performance of standard medical LSR against ISO 10993 test requirements, the global benchmark for biological evaluation of medical devices.
For long-term implantable LSR parts (defined as >30 days of in vivo contact), additional testing confirms resistance to fibrous capsule formation: independent in vivo studies in porcine models show that medical LSR elicits a 40% thinner surrounding tissue capsule than polyurethane (PU) implants after 12 months of implantation, reducing the risk of chronic inflammation and device encapsulation failure. LSR is also inherently compatible with pharmaceutical formulations, with extractable/leachable (E&L) levels 90% lower than PVC seals in peristaltic pump applications for intravenous (IV) drug delivery, per 2023 data from the International Society for Pharmaceutical Engineering (ISPE).
LSR’s tunable mechanical properties allow manufacturers to customize components for use cases ranging from flexible catheter balloons to rigid surgical instrument handles, without compromising material stability. Medical-grade LSR formulations are available in durometer ratings from 10 Shore A (ultra-soft) to 80 Shore D (semi-rigid), with elongation at break ranging from 150% to 900% depending on cross-link density. This versatility eliminates the need for material blending or overmolding in many applications, reducing supply chain complexity and biocompatibility testing burdens.
For dynamic components such as check valves in insulin pumps or piston seals in surgical robots, LSR exhibits exceptional fatigue resistance: standard medical LSR can withstand over 10 million actuation cycles at 30% compression with less than 5% permanent set, compared to 2 million cycles for nitrile rubber seals before failure. LSR also maintains dimensional stability across extreme temperature ranges common in medical workflows, with a continuous operating range of -65°C to 205°C, and short-term resistance to 300°C autoclave cycles. This stability ensures that LSR parts do not warp, shrink, or degrade after repeated sterilization cycles: testing shows that LSR components retain 97% of their original tensile strength after 100 cycles of steam autoclaving at 134°C, compared to 62% for polypropylene (PP) parts under the same conditions.
Additional functional benefits include inherent low surface tension, which reduces protein and bacterial adhesion by 65% compared to PU, per independent microbiological testing. LSR surfaces also support a range of secondary modifications, including plasma coating for enhanced hydrophilicity (contact angle <20°) for catheter guidewires, or hydrophobic coating for water-repellent surgical mask valves, without compromising biocompatibility.
Medical device components must withstand repeated or terminal sterilization without losing functional performance, and LSR is unique among elastomers in its compatibility with all common commercial sterilization methods. This eliminates the need for custom sterilization workflows for LSR-containing devices, reducing manufacturing costs and regulatory validation burdens. Table 2 compares LSR performance across leading sterilization modalities after 10 repeated cycles.
Unlike PVC or PE, LSR does not require post-sterilization aging to remove residual toxins, and it does not emit volatile organic compounds (VOCs) during sterilization, making it ideal for use in closed-system drug delivery devices where contamination risks are high. For implantable components, gamma irradiation stability allows for terminal sterilization in final packaging, eliminating post-assembly contamination risks and reducing quality control costs.
All medical device LSR parts are subject to rigorous regional and international regulatory requirements, which vary based on device classification, duration of patient contact, and intended use. Compliance with these standards is mandatory for market access in all major jurisdictions, and requires full traceability of raw materials, manufacturing processes, and finished part testing.
The two foundational global standards governing medical LSR parts are ISO 10993 (Biological Evaluation of Medical Devices) and ISO 13485 (Quality Management Systems for Medical Devices). ISO 10993 specifies a risk-based approach to biocompatibility testing, with more stringent requirements for parts that have prolonged contact with blood or internal tissue: for example, Class III implantable LSR parts require 6 months of in vivo biocompatibility testing, while Class I surface contact parts only require cytotoxicity and sensitization testing. ISO 13485 mandates full traceability of every LSR part from raw material batch to end user, including documented records of all process parameters, quality tests, and distribution records.
Regional regulators have additional specific requirements for LSR components:
Beyond regulatory compliance, medical LSR parts are subject to standardized material and functional testing to ensure consistency across production batches. Raw material testing is conducted on every incoming LSR batch to verify purity, curing kinetics, and absence of contaminants, including:
Finished part testing is conducted on a lot-to-lot basis, with AQL (Acceptable Quality Limit) sampling rates ranging from 0.4% for low-risk Class I parts to 100% inspection for Class III implantable components. Core finished part tests include:
For custom LSR parts used in novel devices, manufacturers are also required to conduct application-specific performance testing: for example, LSR pacemaker lead insulation requires 10 years of accelerated flex testing to confirm resistance to in vivo fatigue, while LSR infant formula pump seals require testing for migration of substances into food matrices per FDA 21 CFR Part 177.
The performance and regulatory compliance of medical LSR parts depend entirely on tightly controlled manufacturing processes, as LSR’s low viscosity and rapid curing kinetics create unique challenges for precision part production. Unlike thermoplastic injection molding, LSR processing requires closed-loop process monitoring to prevent contamination, ensure consistent curing, and maintain dimensional accuracy across high-volume production runs.
All medical LSR parts must be manufactured in ISO 14644-1 certified cleanroom environments, with cleanroom class determined by the part’s intended use:
Material handling protocols are designed to eliminate cross-contamination between medical and industrial LSR formulations: dedicated LSR metering units with stainless steel contact surfaces are used to transfer the two-part LSR resin (A and B components) from sealed drums to injection molding machines, with in-line filtration to remove particulates >0.2 μm before molding. Platinum curing agents are stored in temperature-controlled, light-proof containers to prevent premature curing, and all contact surfaces are sanitized with isopropyl alcohol between production runs to prevent cross-contamination between different LSR formulations.
For drug-contacting LSR parts, additional material controls include batch-specific testing for bioburden before molding, with limits of <10 CFU per 100 cm² of material, to reduce the burden of terminal sterilization.
LSR injection molding is a high-precision process that requires closed-loop control of temperature, pressure, and curing time to ensure consistent part quality. Unlike thermoplastics, which are melted and injected into cold molds, LSR is injected as a low-viscosity liquid (1,000-100,000 cP) into heated molds, where it cross-links in 10-60 seconds depending on part thickness. Table 3 summarizes standard process parameters for medical LSR molding of common part types.
Advanced process monitoring systems are used to track 12+ process parameters in real time, including injection flow rate, mold cavity pressure, and cross-linking temperature, with automatic rejection of parts produced outside of specified parameter ranges. For micro-precision parts with features <0.1 mm, such as microneedle arrays for transdermal drug delivery, in-line optical inspection is conducted on every part to detect mold flash, short shots, or dimensional deviations that are not visible to the naked eye.
Overmolding is a common process for medical LSR parts, where LSR is molded directly onto thermoplastic substrates (such as polycarbonate or PE) to create multi-material components such as surgical instrument handles with soft-grip LSR surfaces, or catheter hubs with integrated LSR seals. The overmolding process requires precise surface treatment of the thermoplastic substrate (typically plasma treatment) to achieve a bond strength of >3 N/mm between LSR and the substrate, eliminating delamination risks during use.
Post-molding processing for medical LSR parts is designed to remove residual impurities and prepare parts for final assembly or sterilization. The most common post-processing step is post-curing, where parts are heated to 200°C for 2-4 hours in a convection oven to remove residual volatile oligomers and unreacted curing agents, reducing extractable levels by up to 90% compared to non-post-cured parts. For implantable LSR parts, post-curing is followed by additional solvent extraction with ethanol or supercritical CO₂ to further reduce residual contaminants to <1 ppm, per FDA requirements for long-term implants.
Additional post-processing steps include:
Final quality validation includes batch release testing, where a sample of parts from every production lot is tested for biocompatibility, dimensional accuracy, and functional performance before release to customers. For Class III implantable parts, every individual part is marked with a unique serial number to enable full traceability through the supply chain and post-market surveillance.
Medical device LSR parts have become an indispensable component of modern medical technology, offering an unmatched combination of biocompatibility, durability, and process scalability that addresses critical unmet needs in acute care, chronic disease management, and surgical intervention. The intrinsic material properties of LSR, including resistance to extreme temperatures, low protein adhesion, and tunable mechanical performance, enable device manufacturers to create more reliable, patient-safe components than would be possible with conventional thermoplastics or elastomers.
As regulatory requirements for medical devices become more stringent, particularly for long-term implantable and drug delivery applications, the demand for validated, high-quality LSR parts will continue to grow. Future innovations in LSR formulation, including bioresorbable LSR for temporary implant applications and antimicrobial LSR doped with silver ions or metal-organic frameworks (MOFs), will further expand the use cases for LSR in medical devices, with projections that LSR will capture 80% of the medical elastomer component market by 2035. For device manufacturers, partnering with LSR suppliers that have deep expertise in medical regulatory compliance, precision molding, and material science will be critical to bringing next-generation medical devices to market efficiently and safely.
The standardization of LSR testing and manufacturing protocols, combined with ongoing advances in material science, will continue to drive down costs and improve patient outcomes, making LSR the material of choice for medical device components for